hormones researchMale Fertility Supplements: What the Evidence Actually Shows in 2026
Male factor causes 40–50% of infertility. We tier-ranked the evidence on CoQ10, ashwagandha, zinc, vitamin D, and L-carnitine so you know what's worth taking.
In 2020, a team at the National Institutes of Health published a randomized, placebo-controlled trial in JAMA — 2,370 couples undergoing infertility treatment, co-primary outcomes of live birth and semen quality. The treatment arm received daily folic acid and zinc supplementation. The result: no improvement in live birth rates, no meaningful change in sperm concentration or motility. Zero difference.
That trial — the largest of its kind ever run — should have been a corrective to the industry-wide assumption that supplementing folic acid and zinc universally improves male fertility. It mostly wasn't. The supplements kept selling.
This is the gap that makes honest evidence review necessary. Male fertility supplements are a $400 million market built on a mixture of legitimate science, small pilot trials, and wishful extrapolation. Some of what's sold genuinely works — for specific men, at specific doses, over a biologically adequate time window. Most of it is either untested at meaningful doses, tested only in deficient populations, or sold in combinations that make individual efficacy impossible to measure.
Here is what the peer-reviewed data actually says.
Why Male Factor Stays Underdiagnosed
Male factor contributes to roughly 40–50% of infertility cases. That means in half of all couples who cannot conceive, the primary or contributing cause involves sperm quality — count, motility, morphology, or DNA integrity. Yet the clinical default, especially in primary care, remains referring the female partner first for hormonal workup and ovarian reserve testing. The male gets a semen analysis later, if at all.
This has a measurable cost. Men in a struggling partnership spend months or years optimizing female fertility protocols — cycle tracking, hormone therapy, IUI — while the actual constraint is upstream in the male reproductive system. A basic semen analysis costs less than $200. It should be step one.
What makes male fertility particularly addressable through lifestyle and targeted supplementation is that spermatogenesis is a continuous, renewable process. Unlike oocytes, sperm are manufactured constantly. The cells that will appear in a man's ejaculate three months from now do not yet exist. Every factor that influences spermatogenesis — sleep architecture, cortisol load, heat exposure, micronutrient status, mitochondrial function — acts on an ongoing production line. This means the system is more responsive to intervention than most people assume. It also means evaluation requires patience: one complete spermatogenesis cycle is 72–90 days. No supplement can be meaningfully assessed in less than three months.
What a Semen Analysis Actually Measures
Before deciding what to supplement, understand what the numbers mean. The standard semen analysis measures five parameters:
- Total sperm count: Total sperm in an ejaculate (normal ≥39 million)
- Sperm concentration: Sperm per milliliter (normal ≥16 million/mL)
- Total motility: Percentage of sperm moving (normal ≥42%)
- Progressive motility: Percentage moving forward in a straight or large-circle pattern (normal ≥30%)
- Morphology: Percentage with normal head, midpiece, and tail structure by Kruger strict criteria (normal ≥4%)
Most supplements that show effects in trials improve motility and morphology more reliably than they increase count. This matters for interpreting study outcomes and setting realistic expectations.
A second parameter that standard SA does not capture is Sperm DNA Fragmentation Index (DFI). High DFI (>25–30%) predicts poor IVF and IUI outcomes even when all five standard parameters appear normal. Men who have failed two or more cycles with normal SA results should request DFI testing. Oxidative stress is the dominant driver of DNA fragmentation — and this is where antioxidant supplementation has its most defensible mechanism.
Tier 1: Supplements With Consistent Human Trial Evidence
CoQ10 (Ubiquinol Form)
Coenzyme Q10 is the most evidence-backed male fertility supplement in this category. It functions in two roles simultaneously: as a rate-limiting cofactor in the mitochondrial electron transport chain (sperm energy production is almost entirely mitochondria-dependent) and as a lipid-soluble antioxidant protecting sperm from oxidative DNA damage.
A 2009 randomized trial by Safarinejad enrolled 212 men with idiopathic oligoasthenoteratozoospermia (low count, poor motility, abnormal morphology) and randomized them to 300 mg CoQ10 daily or placebo for 26 weeks. The treatment group showed significant improvements in sperm density, motility, and morphology compared to baseline, with the effect sustained at the 12-week follow-up after stopping supplementation.
A 2024 systematic review and meta-analysis in Frontiers in Pharmacology pooled eight eligible RCTs totaling 877 subjects. The pooled direction was consistently positive for motility and morphology in men with idiopathic infertility.
Critical point on form: The CoQ10 molecule exists in oxidized (ubiquinone) and reduced (ubiquinol) states. Ubiquinol — the biologically active antioxidant form — has approximately 2–4 times higher oral bioavailability in most individuals. Men over 35 have a reduced capacity to convert ubiquinone to ubiquinol endogenously. For fertility purposes, ubiquinol at 200–400 mg/day is the evidence-supported choice. Take with a fat-containing meal.
Ashwagandha (KSM-66 Extract)
The most-cited randomized trial in the male fertility supplement literature comes from Ambiye et al. in 2013. Forty-six oligospermic men received either 675 mg/day of KSM-66 ashwagandha root extract (in three divided doses) or placebo for 90 days. At the 90-day mark, the treatment group showed:
- Sperm concentration: +167% (9.59 → 25.61 million/mL)
- Sperm motility: +57%
- Semen volume: +53%
- Serum testosterone: +17%
These are compelling numbers — but the study was small (46 men), and the population was men with documented oligospermia. The large percentage gains reflect low baseline values, not extraordinary effect sizes. KSM-66 appears to work primarily as a hormonal normalizer via HPA axis modulation — reducing cortisol, preserving testosterone, and restoring the upstream hormonal environment that spermatogenesis depends on.
For men with normal sperm parameters, the fertility-specific data is thin. Ashwagandha's testosterone-supporting effects are better established in men with suboptimal hormonal environments. If a man's total testosterone is below 500 ng/dL and he is chronically stressed, KSM-66 at 300–600 mg/day is a reasonable addition. If testosterone is already optimized, the fertility effect is speculative.
One critical caveat: Ashwagandha has thyroid-stimulating properties. Men with hyperthyroidism or autoimmune thyroid conditions should avoid it. Also avoid if on immunosuppressive therapy.
Vitamin D (Deficiency Correction)
Vitamin D receptors are expressed in the testes, Sertoli cells, and sperm themselves. The biological mechanism linking vitamin D status to spermatogenesis is established. The clinical evidence for supplementation is nuanced.
A 2023 systematic review and meta-analysis of five randomized trials (648 infertile men total) found that vitamin D supplementation significantly improved total sperm motility (mean difference +4.96 percentage points) and progressive motility (+4.14 percentage points) versus placebo. Sperm count and concentration did not differ significantly between groups.
The clinical translation: vitamin D supplementation improves motility, not count — and this effect is most pronounced in men who are deficient (serum 25(OH)D <20 ng/mL). Men with levels above 40 ng/mL are unlikely to see a fertility response from further supplementation.
Test serum 25(OH)D before supplementing. Target 40–60 ng/mL. Dose accordingly — typically 2,000–5,000 IU/day for most men starting below 30 ng/mL. Retest at 12 weeks.
Sperm quality is a proxy for male metabolic and hormonal health overall. A man who produces optimal sperm at 38 is not just fertile — he is biologically younger than a man with poor parameters at the same age.
Tier 2: Promising Evidence, More Data Required
L-Carnitine and Acetyl-L-Carnitine
L-carnitine is essential for sperm energy metabolism — it transports long-chain fatty acids into mitochondria, where the ATP sperm need for motility is generated. Seminal plasma L-carnitine concentrations correlate with sperm motility across populations.
A 2022 network meta-analysis in Frontiers in Endocrinology covering 23 RCTs and 1,917 patients ranked L-carnitine as the most effective single intervention for improving sperm motility (WMD +6.52%, 95% CI 2.55–10.05%) and morphology in men with idiopathic male infertility.
The consistent finding across multiple meta-analyses: L-carnitine reliably improves sperm motility parameters. The consistently missing finding: no meta-analysis has demonstrated a significant effect on clinical pregnancy rates. Improved motility in a lab does not automatically translate to improved conception probability — particularly for couples attempting natural conception, where many other factors intervene.
Dosing: Trials typically use 1–3 g/day of L-carnitine, or a combination of L-carnitine (2 g/day) + acetyl-L-carnitine (1 g/day). Take with meals.
Omega-3 (EPA + DHA)
Docosahexaenoic acid (DHA) is a major structural component of the sperm tail's mitochondrial sheath. Sperm cell membrane fluidity — which affects capacitation, acrosome reaction, and fertilization capacity — depends on adequate DHA content. Low seminal plasma omega-3 levels are associated with poor sperm morphology across observational data.
Small RCTs show improvements in progressive motility and morphology with 2–3 g/day of combined EPA+DHA supplementation. No large trial has run on this intervention. High-quality fish oil at 2–3 g/day EPA+DHA is low-risk and plausibly beneficial.
Selenium
Selenium functions as a cofactor for the antioxidant enzyme glutathione peroxidase, which protects sperm DNA from oxidative attack. Low selenium intake is associated with poorer sperm motility and higher oxidative stress markers in infertile men.
The evidence problem: there is no large, well-designed RCT testing selenium supplementation alone for male fertility outcomes. Studies showing benefit have used selenium as part of multi-ingredient antioxidant stacks (CoQ10 + selenium + zinc + B vitamins), making attribution impossible. Men in deficient populations (selenium-poor soils include large parts of Europe) benefit most from correction. Target dose: 100–200 mcg/day of selenomethionine.
What the Data Does Not Support — The Honest Tier
Most articles in this category avoid the negative findings. These are worth stating clearly.
Folic acid + zinc (high dose): The 2020 JAMA trial — 2,370 couples, rigorous design — showed no improvement in live birth rates or semen parameters with daily folic acid (5 mg) and zinc (30 mg) supplementation. This is the largest male fertility supplement RCT ever run. The negative result does not mean zinc is useless — it means supplementing zinc in men already in the normal range does not improve outcomes. It reinforces the deficiency-correction model.
Maca root (Lepidium meyenii): Frequently marketed for male fertility. The human trial evidence is weak — mostly small, short-duration, and methodologically limited. Maca may mildly improve sexual desire and self-reported libido, but sperm quality effects are unestablished in rigorous trials.
Fenugreek: Observational data links fenugreek extracts to modest testosterone elevation. There is no meaningful randomized trial evidence that fenugreek supplementation improves semen parameters. A testosterone signal is not a fertility signal — the mechanisms are distinct.
Antioxidant megadosing: Oxidative stress damages sperm DNA — this is established. The solution is not maximum antioxidant dose. Sperm require a controlled level of reactive oxygen species (ROS) for key functions: capacitation, hyperactivation, and the acrosome reaction. High-dose antioxidant supplementation can paradoxically impair these processes by quenching the ROS that sperm need to function. Meta-analyses confirm that moderate antioxidant doses improve outcomes; the dose-response curve is not linear.
Testosterone replacement therapy + trying to conceive: This is the most important warning in this article. Exogenous testosterone — injectable, topical, or pellet — suppresses the hypothalamic-pituitary-gonadal axis. FSH (which drives Sertoli cell function and spermatogenesis) and LH (which stimulates Leydig cell testosterone production) both drop near zero on TRT. The result is spermatogenesis suppression, often to azoospermia (zero sperm count) within 3–6 months. Men on TRT who want to conceive have several options — HCG co-administration, enclomiphene, or TRT cessation with Clomid — but all require a urologist or reproductive endocrinologist. This is not a supplement-layer decision.
Biomarkers to Establish Before You Spend
Supplementation without baseline testing is guesswork. Before spending money on fertility supplements, run these labs:
- Semen analysis — Two separate tests, ideally 8–12 weeks apart (test-to-test variability is significant). This is the foundation.
- Total testosterone, LH, FSH — If LH and FSH are elevated with low testosterone, the issue is testicular; if all three are low, the issue is hypothalamic/pituitary.
- Serum 25(OH)D (vitamin D) — Deficiency correction produces reliable motility improvement.
- Serum zinc — Correction of documented deficiency is worthwhile; supplementing men in the normal range is not.
- Prolactin — Elevated prolactin suppresses GnRH, LH, and testosterone. A finding here leads to an MRI, not a supplement stack.
- Sperm DNA Fragmentation Index (DFI) — If two or more normal semen analyses have preceded treatment failure, DFI testing reveals the hidden layer. DFI >25–30% is actionable and may redirect treatment toward antioxidant protocols or varicocele repair.
The 90-Day Protocol
There is no supplement that changes next month's semen analysis. The 72–90 day spermatogenesis cycle is the biological constant around which any intervention must be built. Here is the evidence-based starting framework:
- Baseline semen analysis — Get this done before starting any supplement. Request morphology by Kruger strict criteria, not WHO normal forms.
- Lab baseline — Testosterone (total + free), LH, FSH, 25(OH)D, serum zinc, prolactin.
- Correct deficiencies first — If vitamin D is below 30 ng/mL, supplement to 40–60 ng/mL before adding other interventions. If zinc is low, correct it.
- CoQ10 (ubiquinol) — 200–400 mg/day with a fat-containing meal. This is the highest-confidence single supplement.
- L-carnitine — 1.5–2 g/day; add if motility is the primary concern.
- KSM-66 ashwagandha — 300–600 mg/day if total testosterone is below optimal range or if chronic stress is a documented factor.
- EPA + DHA — 2–3 g/day combined; morphology concern or low omega-3 diet.
- Sleep 7.5–8.5 hours — Testosterone and LH pulse primarily during sleep. Chronic sleep restriction directly suppresses spermatogenesis. No supplement corrects this.
- Scrotal temperature — Testicular temperature must stay 2–4°C below core. Avoid prolonged hot tub exposure, tight underwear, laptop heat, heated car seats during active conception attempts.
- 90-day retest — Semen analysis at day 90. Compare to baseline. If motility or count has not improved, re-evaluate the hormone panel before escalating supplements.
Sperm quality is a proxy for male metabolic and hormonal health at large. A man who optimizes his spermatogenesis through sleep, stress management, micronutrient status, and targeted supplementation is not just addressing fertility — he is measurably improving the underlying biology that drives performance, cognition, and longevity. The intervention stack overlaps almost entirely with general male health optimization.
Track your testosterone optimization score — hormonal status and sperm quality are tightly linked, and the score captures the input variables that matter most.